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Abstract
Background: Oxidative stress is heavily implicated in the pathogenic process of Parkinson’s disease. Varying
capacity to detoxify radical oxygen species through induction of phase II antioxidant enzymes in substantia nigra
may influence disease risk. Here, we hypothesize that variation in NFE2L2 and KEAP1, the genes encoding the two
major regulators of the phase II response, may affect the risk of Parkinson’s disease.
Methods: The study included a Swedish discovery case-control material (165 cases and 190 controls) and a Polish
replication case-control material (192 cases and 192 controls). Eight tag single nucleotide polymorphisms
representing the variation in NFE2L2 and three representing the variation in KEAP1 were chosen using HapMap
data and were genotyped using TaqMan Allelic Discrimination.
Results: We identified a protective NFE2L2 haplotype in both of our European case-control materials. Each
haplotype allele was associated with five years later age at onset of the disease (p = 0.001) in the Swedish material,
and decreased risk of PD (p = 2 × 10
-6), with an odds ratio of 0.4 (95% CI 0.3-0.6) for heterozygous and 0.2 (95% CI
0.1-0.4) for homozygous carriers, in the Polish material. The identified haplotype includes a functional promoter
haplotype previously associated with high transcriptional activity. Genetic variation in KEAP1 did not show any
associations.
Conclusion: These data suggest that variation in NFE2L2 modifies the Parkinson’s disease process and provide
another link between oxidative stress and neurodegeneration.
Background
Oxidative stress has been implicated as a major contri-
buting factor in neurodegenerative diseases in general
and Parkinson’s disease (PD) in particular [1]. Cellular
responses to oxidative stress are major determinants of
disease susceptibility and aging, particularly in tissues
that are sensitive to oxidative stress, such as the cen-
tral nervous system [2,3]. In PD brain specimens, signs
of oxidative stress are especially prominent in the sub-
stantia nigra. This may be the result of combined pre-
sence of a high dopamine metabolism generating
reactive oxygen species (ROS), low levels of antioxidant
glutathione and increased levels of iron catalyzing ROS
formation [4]. Furthermore, genetic aberrations in oxi-
dative responses may cause neurodegenerative diseases.
Examples include mutations in SOD1 (encoding super-
oxide dismutase 1) that cause amyotrophic lateral
sclerosis [5] and loss of function mutations in DJ-1
(encoding Parkinson disease protein 7) that leads to
early onset PD with high penetrance [6].
Nuclear factor-erythroid 2 (NF-E2)-related factor 2
(Nrf2) is a member of the cap ‘n’ collar family of basic
leucine zipper transcription factors that regulate the
expression of many antioxidant pathway genes in the
so-called phase II response [7]. Nrf2 is maintained at
basal levels in cells by binding to its inhibitor protein,
Kelch-like erythroid-cell-derived protein with CNC
homology (ECH)-associated protein 1 (Keap1) [8,9].
Keap1 is a BTB (Broad complex, Tramtrack, Bric-a-
Brac) domain-containing protein [9] that targets Nrf2
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tive degradation [10-13]. Upon exposure to oxidative
stress, xenobiotics, or electrophilic metabolites of phase
I enzymes, repression of Nrf2 by Keap1 ubiquitination is
disrupted and newly produced Nrf2 enters the nucleus
[14]. There, it forms heterodimers with other transcrip-
tion regulators, such as small Maf proteins, and induces
the expression of antioxidant phase II genes through
interaction with the antioxidant responsive element
(ARE) in the promoter of these genes [15,16]. Binding
of Nrf2 to ARE drives the expression of phase II
enzymes, such as NQO1 [NAD(P)H dehydrogenase
(quinine) 1] and HO-1 (Heme oxygenase 1), that gener-
ate antioxidant molecules, such as glutathione [17,18].
Nrf2 has been shown to protect neurons from acute
injury in culture [19-21] and in vivo [22]. Furthermore,
upregulation of Nrf2 activity in astrocytes delays motor
neuron degeneration in a mouse model of familial
amyotrophic lateral sclerosis [23].
A p a r tf r o mt h eu n d i s p u t e dinvolvement of oxidative
stress in the PD process [1] there are additional and
more specific links between Nrf2 function and PD. First,
nuclear localization of Nrf2 is induced in PD-affected
substantia nigra, even though the response appears
insufficient to protect neurons from degeneration [24].
Second, treatment of nigrostriatal cultures with Nrf2
activators protects from oxidative stress-induced loss of
dopaminergic cells [25]. Third, a recently discovered
function of DJ-1 is to stabilize Nrf2 by preventing its
interaction with Keap1 [26]. Fourth, recent and quite
striking data show that induced expression of Nrf2 in
brains of transgenic mice protects from MPTP (1-
methyl-4-phenyl-1,2,3,6-tetrahydropyridine)-caused
damage to the nigrostriatal dopaminergic pathway as
seen in PD [27].
Despite these extensive preclinical data, no association
has as yet been demonstrated between NFE2L2 and
KEAP1, the Nrf2 or Keap1 encoding genes, and neuro-
degenerative disease [28]. Here, we have, for the first
time, performed a complete haplotype analysis of the
NFE2L2 and KEAP1 genes in relation to risk of PD in
two independent case-control materials. We found
strong protective effects of an NFE2L2 haplotype in two
independent case-control materials, indicating that vary-
ing efficiency in the oxidative protection by Nrf2 may
influence PD pathogenesis.
Methods
Case-control materials
The Swedish discovery material consisted of 165 PD
cases and 190 age-matched controls. All individuals
were of Caucasian origin. The cases fulfilled the Parkin-
son’s Disease Society Brain Bank criteria for idiopathic
P D[ 2 9 ] ,e x c e p tf o rt h a tt h ep r e s e n c eo fm o r et h a no n e
relative with PD was not considered an exclusion criter-
ion. PD cases with an age at onset (AAO) of <50 years
were screened to exclude that they were carriers of
recognized PD-causing mutations in the DJ-1, Parkin,
PINK1 and LRRK2 genes [30,31]. Demographic charac-
teristics are given in table 1.
The Polish replication material consisted of 192 PD
cases and 192 sex-matched controls. Controls were cho-
sen to be of as high age as possible when included in
the study to minimize the number of controls develop-
ing PD later in life. All individuals were of Caucasian
origin and had no familial aggregation of PD. Demo-
graphic characteristics are given in table 1.
Tag SNP selection
Single nucleotide polymorphism (SNP) genotyping data
covering NFE2L2 and KEAP1 for the European material
CEU (Utah residents with ancestry from northern and
western Europe) were downloaded from the International
Haplotype Mapping Project web site http://www.hapmap.
org[32] and processed in the Haploview software [33].
Linkage disequilibrium (LD) blocks were constructed
according to Gabriel et al. [34] and tag SNPs were
assigned using the tagger function [33]. A minor allele fre-
quency of ≥ 5% and pair wise tagging with a minimum r
2
of 0.80 were applied to capture the common variations
within the blocks covering NFE2L2 and KEAP1. The com-
mon genetic variation of NFE2L2 was tagged for by eight
tag SNPs: rs16865105, rs7557529, rs2886161, rs1806649,
rs2001350, rs10183914, rs2706110 and rs13035806, and
Table 1 Demographic characteristics of PD cases and
controls
Parameter Parkinson Control p-value
1
Swedish cases and controls
Number of subjects 165 190
Age at sampling (years) 68.2 ± 8.8 69.1 ± 9.3 0.698
Age at onset (years) 59.0 ± 10.2 ——
Sex (Female) 71 (43.0) 120 (63.2) <0.001
(Male) 94 (57.0) 70 (36.8)
Current smoker 9 (8.7) 13 (8.3) 0.897
Ever smoked 38 (36.9) 81 (51.6) 0.020
Parkinson’s disease in family 40 (24.8) 18 (9.5) <0.001
Alzheimer’s disease in family 7 (4.3) 8 (4.3) 0.976
Polish cases and controls
Number of subjects 192 192
Age at sampling (years) 63.7 ± 10.9 72.9 ± 9.9 <0.001
Age at onset (years) 55.2 ± 10.9 ——
Sex (Female) 75 (39.1) 75 (39.1) 1.000
(Male) 117 (60.9) 117 (60.9)
Data are presented as absolute numbers (%) or mean ± SD.
1p-values are
calculated with c
2-test for categorical parameters and Mann-Whitney U test
for continuous parameters.
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rs1048287 (figure 1, table 2).
Tag SNP genotyping
Tag SNPs were genotyped using genomic DNA
extracted from blood. TaqMan® Pre-Designed SNP gen-
otyping assays as well as TaqMan® Custom Made SNP
genotyping assays (Applied Biosystems, Foster City, CA,
USA) were used (table 2) according to the TaqMan
Allelic Discrimination technology [35] on the ABI
PRISM 7900HT Sequence Detection System (Applied
Biosystems, Foster City, CA, USA).
Promoter sequencing
Promoter SNPs rs35652124, rs6706649 and rs6721961
were genotyped by sequencing. We amplified a 423 bp
region of the NFE2L2 promoter using forward primer
5’-GACCACTCTCCGACCTAAAGG-3’ and reverse
primer 5’-CGAGATAAAGAGTTGTTTGCGAA-3’,
annealing temperature 59°C and 34 cycles on a PTC-
200 ThermalCycler (Biorad, Hercules, CA, USA). The
product was purified using Illustra™ GFX™ PCR Purifi-
cation Kit (GE Healthcare, Little Chalfont, Buckin-
ghamshire, UK). Sequence reactions were performed
using BigDye v3.1 (Applied Biosystems, Forster City,
CA, USA) and analyzed on an ABI PRISM 3100 Auto-
mated Sequencer (Applied Biosystems, Forster City,
CA, USA). All sequence data were analyzed using the
DNASTAR SeqMan® software (DNASTAR Inc,
Madison, WI, USA).
Statistical Analyses
Demographics for the PD cases and controls were
compared using c
2-statistics for categorical parameters,
i.e. sex, family history of neurodegenerative disorders
and smoking habits, and using Mann-Whitney U test
for age at sampling. Effects of sex, family history of neu-
rodegenerative disease and smoking habits were
Figure 1 Schematic overview of the NFE2L2 (panel A) and KEAP1 (panel B) genes and the tag SNPs used in the study (for rs-numbers
see table 2). Thick black lines indicate exons. The promoter region of NFE2L2 is detailed in panel A.
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using forward stepwise logistic or linear regression in
each material.
All tag SNPs were analyzed for deviation from Hardy-
Weinberg equilibrium using c
2-statistics. Single marker
associations were performed using logistic or linear
regression in an additive model (dd = 0, Dd = 1 and
DD = 2, where D = minor allele and d = major allele).
Haplotype frequencies were estimated in the Helix-
Tree 6.3 software using the expectation-maximization
algorithm [36] yielding all possible haplotypes present in
our materials. In subsequent analyses, however, only
haplotypes with an overall estimated frequency of >1.0%
were included, while the rarer haplotypes were pooled.
In the regression analysis the phase uncertainty for each
individual was taken care of by coding each haplotype
covariate according to the phase probabilities.
The genes were analyzed to identify the haplotype
window with the strongest association to PD diagnosis
and AAO of the disease, and to identify the haplotype
alleles responsible for the association. To this end, we
used a sliding window approach with stepwise forward
logistic or linear haplotype regression including relevant
covariates. The impact of each associated haplotype
allele of the identified window was then investigated
with logistic or linear regression including relevant cov-
ariates. Pairwise LD between the individual tag SNPs
and promoter SNPs was calculated according to Gabriel
et al [34] by means of r
2.
The p-value threshold for statistical significance used
in this study was p = 0.05. To correct for multiple
testing, Bonferroni correction for the number of studied
SNPs was used in all single marker analyses and permu-
tation tests with 10 000 permutations were performed
in the sliding window model. Corrected p-values are
designated as pc. The statistical softwares used were
SYSTAT11 (SYSTAT Software GmbH, Erkrath,
Germany) and HelixTree 6.3 (Golden Helix, Bozeman,
MT, USA).
Ethics
The study was approved by the regional ethics commit-
tee at the University of Gothenburg, Sweden, and the
ethics committee of the Pomeranian Medical University,
Szczecin, Poland and was in compliance with the Hel-
sinki Declaration of 1975. Written informed consent
was obtained from all subjects.
Results
Demographics
Swedish cases and controls were well matched in age.
There were significant differences in the distribution of
sex, family history of PD and smoking habits (table 1).
We identified sex, family history of PD and ever smok-
ing as significantly relevant covariates for the analyses of
association with disease risk. Family history of PD alone
was identified as a significant covariate in analyses of
association with AAO.
Polish cases and controls were matched in sex. Age at
sampling was significantly higher in controls then in PD
cases (table 1). No covariates were identified as signifi-
cantly relevant for the analysis of association with
Table 2 Overview of location and type of the SNPs studied
SNP rs-ID Genome Position Alleles Gene location SNP type TaqMan Assay
NFE2L2 Chr:2(-)
1 rs16865105 177844875 T>G 5’-region — C_33808341_10
2 rs7557529 177843343 G>A 5’-region — C__436313_10
P1 rs35652124 177838319 A>G Promoter (-653) Regulatory
1 Sequencing
2
P2 rs6706649 177838317 G>A Promoter (-651) Regulatory
1 Sequencing
2
P3 rs6721961 177838317 C>A Promoter (-617) Regulatory
1 Sequencing
2
3 rs2886161 177836085 A>G Intron 1 — C__351881_10
4 rs1806649 177826398 G>A Intron 1 — C_11634983_10
5 rs2001350 177808671 A>G Intron 1 — C_11634985_10
6 rs10183914 177805912 G>A Intron 3 — C__157561_10
7 rs2706110 177800408 G>A 3’-region — C_11745133_10
8 rs13035806 177800068 C>T 3’-region — C_11745134_10
KEAP1 Chr:19(-)
1 rs1048287 10471236 T>C Exon 2 Synonymous C___9323068_10
2 rs11085735 10463180 G>T Intron 3 — Custom
3
3 rs1048290 10461442 C>G Exon 4 Synonymous C___9323035_1_
Presented are SNPs numbered according to location on the gene. Genome positions were obtained from the HapMap Genome Browser (Phase 1 & 2 - full
dataset) at the International Haplotype Mapping Project web site http://www.hapmap.org. Alleles are given according to the sense sequence of the gene.
1[37].
2See text for details.
3Forward primer: GCCTCCACTCCCTGAAGAC, reverse primer: GCAAGTCCCAAGACACTGAGATC, probe: TCAGGAAGAAT [C/A]CCCG, primers and
probe were designed according to the anti sense strand of the gene.
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for analysis of association with AAO.
Tag SNP genotyping
None of the studied markers either in the Swedish or
the Polish material had a Hardy-Weinberg equilibrium
p-value of < 0.01. The call rate was >95% for both Taq-
Man genotyping and sequencing.
Association analysis - Swedish material
After correction for multiple testing none of the tag
SNPs alone significantly affected risk of PD (table 3).
The A allele of tag SNP 6 (rs10183914) in NFE2L2 was
estimated to increase AAO of PD with four years per
allele (pc = 0.028). No associations were seen for the
markers in KEAP1 with either risk of PD (table 3) or
AAO in PD (data not shown).
The haplotype window of NFE2L2 consisting of the
five consecutive tag SNPs 2-6 (rs7557529, rs2886161,
rs1806649, rs2001350 and rs10183914) was strongly
associated with risk of PD (pc = 0.008), as well as with
AAO of the disease (pc = 0.003). Phasing of this window
resulted in six haplotypes with a frequency of ≥ 5% in
the PD group (table 4). Within this window, the
haplotypes GAGGG and GAAAG were both associated
with increased risk of PD, with an odds ratio of 2.4
(p = 0.007) and 3.7 (p = 0.010) per haplotype allele,
respectively (table 5). Additionally, the haplotype
GAAAA was estimated to increase AAO of PD with
approximately five years per haplotype allele (p = 7 ×
10
-4, table 5).
With regards to KEAP1, phasing of all three tag SNPs
(rs1048290, rs11085735 and rs1048287) resulted in four
haplotypes with a frequency of ≥ 5% (table 4) without
significant associations with risk or AAO of the disease
(data not shown).
Promoter analysis - Swedish material
SNPs in the NFE2L2 promoter (figure 1) have previously
been shown to affect promoter activity and Nrf2 expres-
sion in vitro [37]. To test the hypothesis that the
observed haplotype associations described above may be
explained by linkage disequilibrium to these functional
polymorphisms, we genotyped all individuals for three
SNPs in the NFE2L2 promoter region by sequencing.
Phasing of the promoter window (rs35652124,
rs6706649 and rs6721961) resulted in four haplotypes
with a frequency of ≥ 5% (table 4). The AGA haplo-
type with low promoter activity [37] showed tendency
to association with increased risk of PD (p = 0.056,
table 5) and was in LD (r
2 = 0.53) with the risk haplo-
type GAGGG. The protective, disease-delaying haplo-
type GAAAA was in LD (r
2 = 0.39) with the promoter
haplotype AGC, i.e. the common promoter variant
associated with full Nrf2 expression. The promoter
SNPs are located between tag SNPs 2 and 3 (figure 1)
and analysis of the full risk haplotype GAGAAGGG
(freq: PD = 10.8%, freq controls = 4.9%) was associated
with risk of PD (p = 0.002) with an odds ratio for PD
of 2.8 per haplotype allele (tab l e5 ) .T h ef u l lp r o t e c t i v e
haplotype GAGCAAAA (freq: PD = 22.5%, freq
controls = 26.4%) was estimated to delay AAO in PD
(p = 0.001) with approximately 5 years per haplotype
allele (table 5).
Replication of NFE2L2 associations - Polish material
In line with the results from the Swedish material, none
of the tag SNPs or promoter SNPs alone had a signifi-
cant effect on the risk of PD after correction for multi-
ple testing (table 3). The observed association of
rs10183914 with AAO in the Swedish material could
not be replicated (data not shown).
In line with the results from the Swedish material, the
haplotype window consisting of tag SNPs 2-6 was asso-
ciated with risk of PD (p = 0.005). The haplotype
GAAAA of this window was associated with decreased
risk of PD (p = 0.005) with an odds ratio of 0.6
(table 5). Notably, this haplotype is identical to the pro-
tective haplotype associated with delayed AAO in the
Swedish material. As in the Swedish material, GAAAA
was in LD (r
2 = 0.42) with the common promoter hap-
lotype AGC. Furthermore, the AGC haplotype alone
showed association with reduced risk of PD (p = 0.003)
with an odds ratio of 0.6 per haplotype allele (table 5).
T h ef u l lp r o t e c t i v eh a p l o t y p eG AGCAAAA (freq:
PD = 12.6%, controls = 27.8%) showed strong associa-
tion with risk of PD (p = 2 × 10
-6) with an odds ratio
f o rP Do f0 . 4f o rh e t e r o z y g o u sc a r r i e r s( t a b l e5 )a n d0 . 2
(95% CI 0.1-0.4) for homozygous carriers. We could not
replicate the risk association of the full haplotype
GAGAAGGG (freq: PD = 5.9%, controls = 9.6%), since
this haplotype showed association with reduced, rather
than increased, risk of PD (p = 0.031) in the Polish
material. There was no association with AAO in the
Polish material (data not shown).
Discussion
To our knowledge, this is the first case-control haplotype
study showing association of the Nrf2-encoding NFE2L2
gene with a neurodegenerative disease. In NFE2L2,w e
found a region, including the promoter, which was clearly
associated with risk of PD in two independent case-con-
trol materials. A haplotype including the fully functional
variant of the promoter (GAGCAAAA) was associated
with delayed AAO in the Swedish material and reduced
risk of PD in the Polish material. These results support
each other and are in agreement with data from animal
and in vitro models suggesting important protective
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SNP
1 rs-ID Genotype Swedish material Polish material
Parkinson
n = 165
2
Control
n = 190
2
p-value
3
(pc-value)
Parkinson
n = 192
2
Control
n = 192
2
p-value
3
(pc-value)
NFE2L2
1 rs16865105 GG 9 (5.5) 18 (9.5) 0.720 10 (5.5) 9 (4.9) 0.716
GT 59 (36.0) 62 (32.6) 58 (32.0) 65 (35.5)
TT 96 (58.5) 110 (57.9) 113 (62.5) 109 (59.6)
2 rs7557529 AA 39 (23.8) 56 (29.5) 0.782 60 (32.1) 49 (27.4) 0.043
AG 85 (51.8) 92 (48.4) 90 (48.1) 75 (41.9) (0.473)
GG 40 (24.4) 42 (22.1) 37 (19.8) 55 (30.7)
P1 rs35652124 GG 15 (9.3) 13 (7.1) 0.564 26 (13.6) 17 (9.1) 0.053
AG 58 (35.8) 89 (48.3) 77 (40.3) 67 (35.8)
AA 89 (54.9) 82 (44.6) 88 (46.1) 103 (55.1)
P2 rs6706649 AA 4 (2.5) 3 (1.6) 1.000 6 (3.1) 2 (1.1) 1.000
AG 33 (20.4) 45 (24.5) 35 (18.3) 42 (22.5)
GG 125 (77.1) 136 (73.9) 150 (78.6) 143 (76.4)
P3 rs6721961 AA 1 (0.6) 1 (0.5) 0.056 6 (3.1) 2 (1.1) 0.833
AC 39 (24.1) 27 (14.7) 38 (19.9) 43 (23.0)
CC 122 (75.3) 156 (84.8) 147 (77.0) 142 (75.9)
3 rs2886161 GG 16 (9.7) 15 (7.9) 0.578 27 (14.4) 17 (9.4) 0.0656
AG 59 (35.8) 91 (47.9) 75 (40.1) 67 (37.0)
AA 90 (54.5) 84 (44.2) 85 (45.5) 97 (53.6)
4 rs1806649 AA 14 (8.5) 15 (7.9) 0.819 9 (4.8) 23 (12.7) 0.011
AG 65 (39.4) 80 (42.1) 60 (32.3) 61 (33.7) (0.121)
GG 86 (52.1) 95 (50.0) 117 (62.9) 97 (53.6)
5 rs2001350 GG 1 (0.6) 0 (0.0) 0.016 4 (2.1) 0 (0.0) 0.663
AG 35 (21.2) 23 (12.1) (0.224) 28 (14.7) 39 (20.9)
AA 129 (78.2) 167 (87.9) 158 (83.2) 148 (79.1)
6 rs10183914 AA 14 (8.5) 25 (13.2) 0.111 20 (10.8) 28 (15.0) 0.254
AG 81 (49.1) 89 (46.8) 73 (39.2) 73 (39.0)
GG 70 (42.4) 76 (40.0) 93 (50.0) 86 (46.0)
7 rs2706110 AA 6 (3.7) 4 (2.1) 0.238 7 (4.0) 1 (0.6) 0.780
AG 48 (29.3) 40 (21.1) 45 (25.4) 53 (30.6)
GG 110 (67.1) 146 (76.8) 125 (70.6) 119 (68.8)
8 rs13035806 TT 2 (1.2) 2 (1.1) 0.796 2 (1.2) 0 (0.0) 0.323
CT 29 (17.7) 27 (14.2) 28 (16.7) 27 (14.9)
CC 133 (81.1) 161 (84.7) 138 (82.1) 154 (85.1)
KEAP1
1 rs1048287 CC 1 (0.6) 2 (1.1) 0.589 ———
CT 35 (21.5) 42 (22.1) ——
TT 127 (77.9) 146 (76.8) ——
2 rs11085735 TT 2 (1.2) 2 (1.1) 0.737 ———
GT 19 (11.7) 24 (12.8) ——
GG 142 (87.0) 162 (86.1) ——
3 rs1048290 GG 22 (13.5) 31 (16.3) 0.372 ———
CG 77 (47.2) 89 (46.9) ——
CC 64 (39.3) 70 (36.8) ——
Data are presented as absolute numbers (percentages).
1For SNP locations see table 2.
2Genotype information available for most cases as specified by the n
numbers.
3p-values were calculated using an additive logistic regression model including statistically relevant covariates.
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[22,23,25], and more specifically, in the nigrostriatal
dopaminergic pathway affected in PD [27].
SNPs in NFE2L2 have previously been investigated
for association with PD in two data sets for which data
is released to the public. The first was a Japanese mul-
tiple candidate gene study [28]. This study included
three NFE2L2 SNPs: rs2886161, rs2886162 and
rs2706112, which showed no evidence of single marker
associations with PD. The other study was an Ameri-
can two tiered whole-genome association study (first:
sib pair, second: case-control) [38]. This study included
six NFE2L2 SNPs (rs2706110, rs10183914, rs6726395,
rs34820876, rs13005431, and rs6433657) of which
none were included in our study. The SNP rs6726395
showed association with PD (p = 9 × 10
-3)i nt h ef i r s t
tier of their study but was not replicated in the second
tier (p = 0.9). This SNP is in LD (r
2 =0 . 9 )w i t h
rs7557529 that in our study showed association with
risk of PD in the Polish material (p = 0.04), but not in
the Swedish (p = 0.8).
The haplotype block identified in the Swedish discov-
ery material consisted of five consecutive tag SNPs that
are located upstream of or in intronic regions of
NFE2L2. The disease-associated haplotypes could thus
influence expression of Nrf2 or be linked to non-synon-
ymous SNPs. However, SNPs that affect transcription
factor function are particularly rare [39] and there are
no non-synonymous SNPs with a reported frequency ≥
5% within NFE2L2 either in HapMap or in the NCBI
SNP database (dbSNP). In addition, the gene and pro-
tein sequences are >80% conserved across mammalian
species, supporting a strong selection pressure against
genetic variation in coding sequences of NFE2L2.
NFE2L2 promoter polymorphisms, on the other hand,
have previously been studied and found to affect
NFE2L2 promoter activity in vitro [37]. Analysis of the
promoter haplotypes in our materials suggests that part
of the haplotype associations with risk of PD is
explained by linkage to these functional promoter SNPs.
Indeed, the protective haplotype GAAAA is in linkage
with the wild type, well functioning version of the pro-
moter AGC, and the full AGC-including haplotype
GAGCAAAA was associated with decreased risk of PD
in the Polish material and older AAO of PD in the
Swedish material.
While an AAO-modifying gene is conceptually not the
same as a risk gene they represent two overlapping con-
cepts. An AAO-modifying gene will easily appear as a
Table 4 Haplotype frequencies in PD cases and controls
Haplotypes
1 Swedish material Polish material
Parkinson Control Parkinson Control
NFE2L2 tag SNPs 2-6
AGGAG 26.2% 30.6% 33.9% 28.2%
AAGAG 22.2% 22.0% 20.5% 20.5%
GAAAA 21.5% 26.7% 18.4% 27.7%
GAGGG 10.9% 5.5% 9.7% 9.6%
GAGAA 10.2% 9.1% 9.9% 7.1%
GAAAG 5.4% 1.7% 1.4% 2.5%
NFE2L2 promoter P1-P3
AGC 47.5% 47.0% 40.8% 48.1%
GGC 27.2% 31.2% 33.8% 27.0%
AAC 12.6% 13.8% 12.3% 12.3%
AGA 12.6% 7.9% 13.1% 12.6%
KEAP1 tag SNPs 1-3
TGC 55.8% 52.7% ——
TGG 26.1% 27.7% ——
CGG 11.0% 12.0% ——
TTC 6.7% 7.4% ——
Data are presented for haplotypes with frequencies ≥ 5.0% estimated with the
EM-algorithm.
1For rs-numbers see table 2.
Table 5 Summary of NFE2L2 haplotypes that influence risk of PD
NFE2L2 Haplotypes
1 Swedish material Swedish material Polish material
Disease Risk (OR/allele)
2 p-value
3 AAO
(Years/allele)
p-value
3 Disease risk
(OR/allele)
2
p-value
3
Tag SNPs 2-6
GAAAA 0.9 (0.6-1.3) 0.450 +4.8 7×1 0
-4 0.6 (0.4-0.9) 0.005
GAGGG 2.4 (1.2-4.5) 0.007 -0.1 0.952 0.9 (0.5-1.5) 0.699
GAAAG 3.7 (1.3-10.6) 0.010 -3.3 0.236 0.5 (0.2-1.6) 0.239
Promoter P1-P3
AGC 0.9 (0.7-1.3) 0.538 +2.1 0.061 0.6 (0.4-0.9) 0.003
Full haplotypes
4
GAGCAAAA 0.9 (0.6-1.4) 0.631 +4.6 0.001 0.4 (0.3-0.6) 2×1 0
-6
GAGAAGGG 2.8 (1.4-5.5) 0.002 -0.3 0.886 0.5 (0.3-1.0) 0.031
GAGCAAAG 3.3 (1.1-9.7) 0.028 -2.5 0.387 0.4 (0.1-1.4) 0.150
1For rs-numbers see table 2.
2Data are given as OR (95% confidence interval).
3p values are calculated with logistic or linear regression models including the
associated haplotypes and significantly relevant covariates in the specified windows.
4tag SNPs 2-6 and promoter SNPs P1-P3 in order according to chromosomal
location (figure 1) with the promoter SNPs highlighted in bold.
von Otter et al. BMC Medical Genetics 2010, 11:36
http://www.biomedcentral.com/1471-2350/11/36
Page 7 of 9risk gene in certain study designs. The two studies differ
substantially in the PD patients’ AAO. The Swedish
patients were on average 4 years older at disease onset
compared with Polish patients. Depending on the shape
of the age-dependent penetrans function for the
NFE2L2 haplotypes, the Polish material may be better
suited for detecting risk associations, while it may be
easier do detect a genetic influence on AAO in the
Swedish material.
In the Polish material the significant association was
as the protective GAAAA haplotype while in the Swed-
ish the GAGGG haplotype was associated with increased
risk. For obvious reasons the presence of a risk/protec-
tive haplotype implies that other haplotypes must be
protective/risk haplotypes. Since the different haplotypes
viewed as covariates are negative confounders (due to
the constraint of a total sum of two haplotypes per indi-
vidual) it is a statistical phenomenon that the regression
analysis can find significance for a protective haplotype
in one material, while in another material a risk haplo-
type is found significant.
KEAP1 showed no association with PD in the Swedish
or the Polish material. This finding is consistent with
the American genome-wide study discussed above in
which three KEAP1 SNPs (rs11085735, rs1048287, and
rs2007529) were included but did not show any associa-
tion with PD [38].
Conclusions
In summary, a common NFE2L2 haplotype influences
risk of PD in two discrete Caucasian case-control mate-
rials. The molecular consequence of this haplotype may
be increased efficiency in the Keap1-Nrf2-ARE response
to oxidative stress and thereby higher capacity to with-
stand endogenous or environmental risk factors for PD.
Further investigations in other populations as well as
functional studies addressing how the disease-associated
NFE2L2 h a p l o t y p ea f f e c t sg e n ee x p r e s s i o na r en o w
needed. To conclude, these results together with recent
preclinical data provide another link between oxidative
stress and the pathogenesis of PD and support NFE2L2
as a novel susceptibility gene for PD.
Acknowledgements
The authors are grateful for the excellent technical assistance of Mrs Mona
Seibt Palmér. This work was supported by grants from the Swedish Research
Council, the Alzheimer’s Association (NIRG-08-90356), cNEUPRO, the Royal
Swedish Academy of Sciences, the Sahlgrenska University Hospital, the West
Sweden RUN fundings, Edith Jacobsson Foundation, Axel Linders
Foundation, the Göteborg Medical Society, the Swedish Medical Society,
Swedish Brain Power, Stiftelsen för Gamla Tjänarinnor, the Swedish Parkinson
Foundation, Gun och Bertil Stohnes stiftelse, the Åhlén Foundation and the
Alzheimer’s Foundation, Sweden. Funding sources played no role in the
design and conduct of the study; collection, management, analysis, and
interpretation of the data; or preparation, review, or approval of the
manuscript.
Author details
1Institute of Neuroscience and Physiology, Department of Psychiatry and
Neurochemistry, The Sahlgrenska Academy at University of Gothenburg, Blå
stråket 15, 413 45 Gothenburg, Sweden.
2Institute of Neuroscience and
Physiology, Department of Pharmacology, The Sahlgrenska Academy at
University of Gothenburg, Box 431, 405 30 Gothenburg, Sweden.
3Institute of
Mathematical Sciences, Department of Mathematical Statistics, Chalmers
University of Technology, Chalmers tvärgata 3, 412 96 Gothenburg, Sweden.
4Institute of Biomedicine, Department of Clinical Chemistry and Transfusion
Medicine, The Sahlgrenska Academy at University of Gothenburg, Bruna
stråket 16, 413 45 Gothenburg, Sweden.
5Department of Pharmacology,
Pomeranian Medical University, Powstancow Wlkp 72, Szczecin 70-111,
Poland.
6Institute of Neuroscience and Physiology, Center for Brain Repair
and Rehabilitation, The Sahlgrenska Academy at University of Gothenburg,
Per Dubbsgatan 14, 413 45, Gothenburg, Sweden.
Authors’ contributions
MVO: Research project - Organization, design; Statistical analysis - Design
and execution; Manuscript - Writing of first draft, review and critique. SL:
Research project - Organization, design; Statistical analysis - Design and
execution; Manuscript - Review and critique. SN: Statistical analysis - Design,
review and critique; Manuscript - Review and critique. DC: Laboratory work -
Execution; Manuscript - Review and critique. PB: Laboratory work -
Execution; Manuscript - Review and critique. AH: Laboratory work - Supplier
of patient material; Manuscript - Review and critique. KB: Research project -
Conception; Manuscript - Review and critique. MD: Laboratory work -
Supplier of patient material; Manuscript - Review and critique. MB:
Laboratory work - Supplier of patient material; Manuscript - Review and
critique. MK: Laboratory work - Supplier of patient material; Manuscript -
Review and critique. HN: Laboratory work - Supplier of patient material;
Manuscript - Review and critique. MN: Research project - Conception;
Manuscript - Review and critique. OH: Research project - Conception;
Manuscript - Review and critique. HZ: Research project - Conception;
Manuscript - Writing of first draft, review and critique. All authors have read
and approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 29 June 2009 Accepted: 2 March 2010
Published: 2 March 2010
References
1. Zhou C, Huang Y, Przedborski S: Oxidative stress in Parkinson’s disease: a
mechanism of pathogenic and therapeutic significance. Ann N Y Acad Sci
2008, 1147:93-104.
2. Kedar NP: Can we prevent Parkinson’s and Alzheimer’s disease?
J Postgrad Med 2003, 49(3):236-245.
3. Nunomura A, Moreira PI, Lee HG, Zhu X, Castellani RJ, Smith MA, Perry G:
Neuronal death and survival under oxidative stress in Alzheimer and
Parkinson diseases. CNS Neurol Disord Drug Targets 2007, 6(6):411-423.
4. Chinta SJ, Andersen JK: Redox imbalance in Parkinson’s disease. Biochim
Biophys Acta 2008, 1780(11):1362-1367.
5. Andersen PM: Amyotrophic lateral sclerosis associated with mutations in
the CuZn superoxide dismutase gene. Curr Neurol Neurosci Rep 2006,
6(1):37-46.
6. Bonifati V, Rizzu P, van Baren MJ, Schaap O, Breedveld GJ, Krieger E,
Dekker MC, Squitieri F, Ibanez P, Joosse M, van Dongen JW, Vanacore N,
van Swieten JC, Brice A, Meco G, van Duijn CM, Oostra BA, Heutink P:
Mutations in the DJ-1 gene associated with autosomal recessive early-
onset parkinsonism. Science 2003, 299(5604):256-259.
7. Kensler TW, Wakabayashi N, Biswal S: Cell survival responses to
environmental stresses via the Keap1-Nrf2-ARE pathway. Annu Rev
Pharmacol Toxicol 2007, 47:89-116.
8. Dhakshinamoorthy S, Jaiswal AK: Functional characterization and role of
INrf2 in antioxidant response element-mediated expression and
antioxidant induction of NAD(P)H:quinone oxidoreductase1 gene.
Oncogene 2001, 20(29):3906-3917.
9. Itoh K, Wakabayashi N, Katoh Y, Ishii T, Igarashi K, Engel JD, Yamamoto M:
Keap1 represses nuclear activation of antioxidant responsive elements
von Otter et al. BMC Medical Genetics 2010, 11:36
http://www.biomedcentral.com/1471-2350/11/36
Page 8 of 9by Nrf2 through binding to the amino-terminal Neh2 domain. Genes Dev
1999, 13(1):76-86.
10. Cullinan SB, Gordan JD, Jin J, Harper JW, Diehl JA: The Keap1-BTB protein
is an adaptor that bridges Nrf2 to a Cul3-based E3 ligase: oxidative
stress sensing by a Cul3-Keap1 ligase. Mol Cell Biol 2004,
24(19):8477-8486.
11. Furukawa M, Xiong Y: BTB protein Keap1 targets antioxidant transcription
factor Nrf2 for ubiquitination by the Cullin 3-Roc1 ligase. Mol Cell Biol
2005, 25(1):162-171.
12. Kobayashi A, Kang MI, Okawa H, Ohtsuji M, Zenke Y, Chiba T, Igarashi K,
Yamamoto M: Oxidative stress sensor Keap1 functions as an adaptor for
Cul3-based E3 ligase to regulate proteasomal degradation of Nrf2. Mol
Cell Biol 2004, 24(16):7130-7139.
13. Zhang DD, Lo SC, Cross JV, Templeton DJ, Hannink M: Keap1 is a redox-
regulated substrate adaptor protein for a Cul3-dependent ubiquitin
ligase complex. Mol Cell Biol 2004, 24(24):10941-10953.
14. Kobayashi A, Kang MI, Watai Y, Tong KI, Shibata T, Uchida K, Yamamoto M:
Oxidative and electrophilic stresses activate Nrf2 through inhibition of
ubiquitination activity of Keap1. Mol Cell Biol 2006, 26(1):221-229.
15. Itoh K, Chiba T, Takahashi S, Ishii T, Igarashi K, Katoh Y, Oyake T, Hayashi N,
Satoh K, Hatayama I, Yamamoto M, Nabeshima Y: An Nrf2/small Maf
heterodimer mediates the induction of phase II detoxifying enzyme
genes through antioxidant response elements. Biochem Biophys Res
Commun 1997, 236(2):313-322.
16. Wild AC, Moinova HR, Mulcahy RT: Regulation of gamma-glutamylcysteine
synthetase subunit gene expression by the transcription factor Nrf2.
J Biol Chem 1999, 274(47):33627-33636.
17. Venugopal R, Jaiswal AK: Nrf1 and Nrf2 positively and c-Fos and Fra1
negatively regulate the human antioxidant response element-mediated
expression of NAD(P)H:quinone oxidoreductase1 gene. Proc Natl Acad Sci
USA 1996, 93(25):14960-14965.
18. Alam J, Stewart D, Touchard C, Boinapally S, Choi AM, Cook JL: Nrf2, a
Cap’n’Collar transcription factor, regulates induction of the heme
oxygenase-1 gene. J Biol Chem 1999, 274(37):26071-26078.
19. Vargas MR, Pehar M, Cassina P, Beckman JS, Barbeito L: Increased
glutathione biosynthesis by Nrf2 activation in astrocytes prevents
p75NTR-dependent motor neuron apoptosis. J Neurochem 2006,
97(3):687-696.
20. Kraft AD, Johnson DA, Johnson JA: Nuclear factor E2-related factor
2-dependent antioxidant response element activation by tert-
butylhydroquinone and sulforaphane occurring preferentially in
astrocytes conditions neurons against oxidative insult. J Neurosci 2004,
24(5):1101-1112.
21. Shih AY, Johnson DA, Wong G, Kraft AD, Jiang L, Erb H, Johnson JA,
Murphy TH: Coordinate regulation of glutathione biosynthesis and
release by Nrf2-expressing glia potently protects neurons from oxidative
stress. J Neurosci 2003, 23(8):3394-3406.
22. Calkins MJ, Jakel RJ, Johnson DA, Chan K, Kan YW, Johnson JA: Protection
from mitochondrial complex II inhibition in vitro and in vivo by Nrf2-
mediated transcription. Proc Natl Acad Sci USA 2005, 102(1):244-249.
23. Vargas MR, Johnson DA, Sirkis DW, Messing A, Johnson JA: Nrf2 activation
in astrocytes protects against neurodegeneration in mouse models of
familial amyotrophic lateral sclerosis. J Neurosci 2008, 28(50):13574-13581.
24. Ramsey CP, Glass CA, Montgomery MB, Lindl KA, Ritson GP, Chia LA,
Hamilton RL, Chu CT, Jordan-Sciutto KL: Expression of Nrf2 in
neurodegenerative diseases. J Neuropathol Exp Neurol 2007, 66(1):75-85.
25. Siebert A, Desai V, Chandrasekaran K, Fiskum G, Jafri MS: Nrf2 activators
provide neuroprotection against 6-hydroxydopamine toxicity in rat
organotypic nigrostriatal cocultures. J Neurosci Res 2009, 87(7):1659-1669.
26. Clements CM, McNally RS, Conti BJ, Mak TW, Ting JP: DJ-1, a cancer- and
Parkinson’s disease-associated protein, stabilizes the antioxidant
transcriptional master regulator Nrf2. Proc Natl Acad Sci USA 2006,
103(41):15091-15096.
27. Chen PC, Vargas MR, Pani AK, Smeyne RJ, Johnson DA, Kan YW,
Johnson JA: Nrf2-mediated neuroprotection in the MPTP mouse model
of Parkinson’s disease: Critical role for the astrocyte. Proc Natl Acad Sci
USA 2009, 106(8):2933-2938.
28. Mizuta I, Satake W, Nakabayashi Y, Ito C, Suzuki S, Momose Y, Nagai Y,
Oka A, Inoko H, Fukae J, Saito Y, Sawabe M, Murayama S, Yamamoto M,
Hattori N, Murata M, Toda T: Multiple candidate gene analysis identifies
alpha-synuclein as a susceptibility gene for sporadic Parkinson’s disease.
Hum Mol Genet 2006, 15(7):1151-1158.
29. Daniel SE, Lees AJ: Parkinson’s Disease Society Brain Bank, London:
overview and research. J Neural Transm Suppl 1993, 39:165-172.
30. Westerlund M, Belin AC, Anvret A, Hakansson A, Nissbrandt H, Lind C,
Sydow O, Olson L, Galter D: Cerebellar alpha-synuclein levels are
decreased in Parkinson’s disease and do not correlate with SNCA
polymorphisms associated with disease in a Swedish material. FASEB J
2008, 22(10):3509-3514.
31. Bergman O, Hakansson A, Westberg L, Nordenstrom K, Carmine Belin A,
Sydow O, Olson L, Holmberg B, Eriksson E, Nissbrandt H: PITX3
polymorphism is associated with early onset Parkinson’s disease.
Neurobiol Aging 31(1):114-117.
32. The HapMap Consortium: The International HapMap Project. Nature 2003,
426(6968):789-796.
33. Barrett JC, Fry B, Maller J, Daly MJ: Haploview: analysis and visualization of
LD and haplotype maps. Bioinformatics 2005, 21(2):263-265.
34. Gabriel SB, Schaffner SF, Nguyen H, Moore JM, Roy J, Blumenstiel B,
Higgins J, DeFelice M, Lochner A, Faggart M, Liu-Cordero SN, Rotimi C,
Adeyemo A, Cooper R, Ward R, Lander ES, Daly MJ, Altshuler D: The
structure of haplotype blocks in the human genome. Science 2002,
296(5576):2225-2229.
35. Livak KJ: Allelic discrimination using fluorogenic probes and the 5’
nuclease assay. Genet Anal 1999, 14(5-6):143-149.
36. Excoffier L, Slatkin M: Maximum-likelihood estimation of molecular
haplotype frequencies in a diploid population. Mol Biol Evol 1995,
12(5):921-927.
37. Marzec JM, Christie JD, Reddy SP, Jedlicka AE, Vuong H, Lanken PN,
Aplenc R, Yamamoto T, Yamamoto M, Cho HY, Kleeberger SR: Functional
polymorphisms in the transcription factor NRF2 in humans increase the
risk of acute lung injury. FASEB J 2007, 21(9):2237-2246.
38. Maraganore DM, de Andrade M, Lesnick TG, Strain KJ, Farrer MJ, Rocca WA,
Pant PV, Frazer KA, Cox DR, Ballinger DG: High-resolution whole-genome
association study of Parkinson disease. Am J Hum Genet 2005,
77(5):685-693.
39. Ramensky V, Bork P, Sunyaev S: Human non-synonymous SNPs: server
and survey. Nucleic Acids Res 2002, 30(17):3894-3900.
Pre-publication history
The pre-publication history for this paper can be accessed here: http://www.
biomedcentral.com/1471-2350/11/36/prepub
doi:10.1186/1471-2350-11-36
Cite this article as: von Otter et al.: Association of Nrf2-encoding NFE2L2
haplotypes with Parkinson’s disease. BMC Medical Genetics 2010 11:36.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
von Otter et al. BMC Medical Genetics 2010, 11:36
http://www.biomedcentral.com/1471-2350/11/36
Page 9 of 9